For the quarter, the company reported revenue in its Discovery and Analytical Solutions segment of $513 million, compared to $391 million for the same period in 2020. It posted operating income from continuing operations for the segment of $64 million, compared to $39 million for the second quarter of last year, and operating income of $101 million, compared to $57 million in the same period in 2020.

In other PerkinElmer news, the company announced that it will acquire antibody and research reagent manufacturer BioLegend for $5.25 billion.

PerkinElmer agrees to acquire Sirion Biotech
PerkinElmer has entered into an agreement to acquire Sirion Biotech, a provider of viral vector-based technology for cell and gene therapies. The acquisition...

PerkinElmer contributes resources to public cell painting dataset
PerkinElmer is providing its PhenoVue cell painting kits to the Joint Undertaking in Morphological Profiling-Cell Painting consortium to help speed drug...

PerkinElmer to acquire Nexcelom for $260M
PerkinElmer has entered into an agreement to acquire life sciences instrumentation firm Nexcelom Bioscience for $260 million, a deal that is expected...

PerkinElmer posts major gains in Q1
PerkinElmer reported sharp increases in revenues and net income for the first quarter of 2021.

PerkinElmer contributes to PROTACs research
PerkinElmer is serving as a provider and co-developer of assays, instruments, and expertise for the ProxiDrugs Consortium, which is zeroing in on research...